Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CRVS on Nasdaq
Shares outstanding
74,361,296
Price per share
$7.70
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
41,673,686
Total reported value
$307,002,895
% of total 13F portfolios
0%
Share change
-114,786
Value change
+$4,353,875
Number of holders
101
Price from insider filings
$7.70
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 12% -11% $35,423,231 9,785,423 0% ORBIMED ADVISORS LLC 12 May 2025
MILLER RICHARD A MD 7.7% $18,897,732 5,220,368 Richard A. Miller 31 Dec 2024
BlackRock, Inc. 5.4% $29,594,309 4,015,510 BlackRock, Inc. 30 Sep 2025

As of 30 Sep 2025, 101 institutional investors reported holding 41,673,686 shares of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS). This represents 56% of the company’s total 74,361,296 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) together control 53% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 9.6% 7,165,006 0% 1.3% $52,806,094
Point72 Asset Management, L.P. 8.7% 6,454,274 -8.4% 0.1% $47,567,999
BlackRock, Inc. 6.3% 4,710,442 +11% 0% $34,715,958
VANGUARD GROUP INC 4.7% 3,471,925 +5.8% 0% $25,588,088
ADAMS STREET PARTNERS LLC 4.4% 3,275,616 0% 16% $24,141,290
RTW INVESTMENTS, LP 3.6% 2,679,479 0% 0.24% $19,747,760
Vivo Capital, LLC 3% 2,234,566 0% 1.3% $16,468,751
Foresite Capital Management VI LLC 2.3% 1,731,233 0% 4.9% $12,759,187
GEODE CAPITAL MANAGEMENT, LLC 2% 1,456,528 +7% 0% $10,736,839
PERCEPTIVE ADVISORS LLC 1.9% 1,438,595 0% 0.31% $10,602,445
STATE STREET CORP 1.4% 1,006,319 +51% 0% $7,416,571
MORGAN STANLEY 0.83% 617,224 -31% 0% $4,548,941
NORTHERN TRUST CORP 0.63% 466,486 +16% 0% $3,438,001
GOLDMAN SACHS GROUP INC 0.6% 445,670 +162% 0% $3,284,588
SPHERA FUNDS MANAGEMENT LTD. 0.55% 407,709 +123% 0.71% $3,004,815
GSA CAPITAL PARTNERS LLP 0.54% 401,407 +26% 0.25% $2,958,000
BARCLAYS PLC 0.42% 309,152 -10% 0% $2,278,448
TWO SIGMA INVESTMENTS, LP 0.27% 203,360 -9.2% 0% $1,498,763
WELLINGTON MANAGEMENT GROUP LLP 0.24% 180,175 +76% 0% $1,327,889
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.24% 177,788 +9.9% 0% $1,310,298
TOWERVIEW LLC 0.23% 170,000 0% 0.91% $1,252,900
Empirical Financial Services, LLC d.b.a. Empirical Wealth Management 0.23% 169,200 +0.71% 0.03% $1,247,004
UBS Group AG 0.22% 162,074 +81% 0% $1,194,485
TWO SIGMA ADVISERS, LP 0.22% 161,600 -24% 0% $1,190,992
BANK OF AMERICA CORP /DE/ 0.2% 151,966 +14% 0% $1,119,989

Institutional Holders of Corvus Pharmaceuticals, Inc. - Common Stock (CRVS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 300,093 $2,310,555 +$298,336 $7.70 7
2025 Q3 41,673,686 $307,002,895 +$4,353,875 $7.37 101
2025 Q2 41,781,497 $167,123,225 +$27,653,733 $4.00 92
2025 Q1 36,268,523 $115,333,082 -$7,370,970 $3.18 87
2024 Q4 37,723,156 $201,818,514 +$34,704,752 $5.35 85
2024 Q3 30,026,264 $158,538,176 +$12,733,385 $5.28 61
2024 Q2 27,591,708 $50,216,835 +$17,655,345 $1.82 46
2024 Q1 17,899,766 $31,860,771 -$2,279,392 $1.78 46
2023 Q4 19,183,314 $33,762,501 +$90,871 $1.76 46
2023 Q3 19,186,334 $28,011,450 -$1,230,958 $1.46 52
2023 Q2 19,491,995 $44,633,999 +$707,708 $2.29 51
2023 Q1 20,767,710 $18,897,208 -$183,902 $0.91 35
2022 Q4 21,363,573 $18,157,963 -$606,364 $0.85 38
2022 Q3 22,082,952 $18,073,081 -$3,458,421 $0.82 38
2022 Q2 25,594,950 $25,339,212 -$3,279,778 $0.99 39
2022 Q1 27,387,121 $44,913,000 -$1,201,434 $1.64 52
2021 Q4 27,678,421 $66,701,000 -$7,831,144 $2.41 58
2021 Q3 28,180,241 $136,388,000 +$22,907,893 $4.84 55
2021 Q2 23,673,230 $63,207,000 +$8,569,595 $2.67 44
2021 Q1 20,393,400 $62,807,000 +$12,093,812 $3.08 45
2020 Q4 16,311,910 $58,071,014 -$3,250,489 $3.56 34
2020 Q3 17,216,699 $69,036,016 -$11,684,715 $4.01 33
2020 Q2 20,440,680 $55,598,011 -$392,205 $2.72 34
2020 Q1 20,651,240 $43,573,167 -$3,308,904 $2.11 36
2019 Q4 20,779,789 $113,038,430 -$10,373,847 $5.44 35
2019 Q3 22,891,685 $68,903,436 -$4,060,912 $3.01 34
2019 Q2 24,342,578 $90,952,754 -$1,503,000 $3.74 43
2019 Q1 24,763,106 $99,529,635 -$1,002,484 $4.02 56
2018 Q4 25,129,757 $92,163,767 -$1,838,747 $3.67 60
2018 Q3 25,496,765 $218,762,586 -$3,322,901 $8.58 60
2018 Q2 25,906,899 $284,454,314 +$6,770,964 $10.98 56
2018 Q1 25,285,587 $287,758,705 +$90,614,709 $11.53 54
2017 Q4 17,418,578 $180,457,571 -$3,160,000 $10.36 53
2017 Q3 17,544,055 $279,715,086 +$1,015,923 $15.94 52
2017 Q2 17,504,516 $211,804,598 -$2,803,453 $12.10 48
2017 Q1 17,335,240 $360,050,125 +$9,744,515 $20.77 52
2016 Q4 17,484,501 $250,048,615 +$17,391,608 $14.30 53
2016 Q3 16,266,787 $267,555,203 -$17,049,726 $16.45 44
2016 Q2 14,645,573 $208,464,147 +$13,774,406 $14.26 43
2016 Q1 13,758,120 $199,086,000 +$197,418,000 $14.50 31